CMC Biologics Expands GMP Manufacturing Capacity in the United States and Europe
-- Company plans to add more than 30,000L of bioreactor capacity across its three sites
COPENHAGEN, Denmark, SEATTLE and BERKELEY, California, May 7, 2015 /PRNewswire/ -- CMC Biologics, Inc., a global leader in clinical and commercial manufacturing, announced today a plan to expand its global manufacturing capacity by more than 30,000 liters in the United States and Europe to meet growing customer demands for late-stage and commercial manufacturing.
Logo - http://photos.prnewswire.com/prnh/20110502/SF93356LOGO
"This global expansion addresses increasing demands from our customers for late-stage and commercial manufacturing," said Gustavo Mahler, PhD, Global Chief Operations Officer of CMC Biologics. "CMC Biologics is investing in innovative facility design to provide the production flexibility needed to meet aggressive regulatory and production timelines and speed our customers' products to market."
Additional information on CMC Biologics' global facility expansion in Copenhagen, Seattle and Berkeley will be released in the following weeks. Follow us on LinkedIn at https://www.linkedin.com/company/cmc-biologics and on our website at www.cmcbiologics.com.
About CMC Biologics
CMC Biologics is leading the industry among CMOs in reliability, technical excellence, and quality — Right and On Time. With three facilities in the USA and Europe, the Company provides fully integrated biopharmaceutical development and manufacturing solutions to clients globally. The Company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical, and commercial production. The Company's wide range of integrated services includes cell line development, bioprocess development, formulation development, and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1® expression system for mammalian production. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. More detailed information can be found at www.cmcbiologics.com.
Share this article